MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ngar Yee Louie Acquires 81,699 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ngar Yee Louie bought 81,699 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were bought at an average price of $1.22 per share, with a total value of $99,672.78. Following the completion of the transaction, the director owned 1,248,888 shares in the company, valued at approximately $1,523,643.36. This trade represents a 7.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MAIA Biotechnology Stock Performance

Shares of NYSEAMERICAN MAIA opened at $1.36 on Wednesday. The stock has a market capitalization of $50.36 million and a P/E ratio of -1.86. The stock’s fifty day moving average is $1.21 and its 200 day moving average is $1.50. MAIA Biotechnology, Inc. has a 52 week low of $0.87 and a 52 week high of $2.74.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.08). Equities research analysts forecast that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current year.

Institutional Investors Weigh In On MAIA Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology in the 2nd quarter valued at $52,000. Marshall Wace LLP acquired a new stake in MAIA Biotechnology in the second quarter valued at about $29,000. Centric Wealth Management grew its position in MAIA Biotechnology by 740.2% in the second quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after acquiring an additional 505,150 shares during the last quarter. Geode Capital Management LLC raised its stake in MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after acquiring an additional 7,746 shares in the last quarter. Finally, Centerpoint Advisory Group acquired a new position in MAIA Biotechnology during the second quarter worth about $28,000. 5.65% of the stock is currently owned by institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.